0000899243-20-030313.txt : 20201103
0000899243-20-030313.hdr.sgml : 20201103
20201103195614
ACCESSION NUMBER: 0000899243-20-030313
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201102
FILED AS OF DATE: 20201103
DATE AS OF CHANGE: 20201103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Epstein David M.
CENTRAL INDEX KEY: 0001488668
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 201284882
MAIL ADDRESS:
STREET 1: OSI PHARMACEUTICALS, INC.
STREET 2: 41 PINELAWN ROAD
CITY: MELVILLE
STATE: NY
ZIP: 11747
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-02
0
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001488668
Epstein David M.
C/O BLACK DIAMOND THERAPEUTICS, INC.
139 MAIN STREET
CAMBRIDGE
MA
02142
1
1
0
0
See Remarks
Common Stock
2020-11-02
4
M
0
3000
6.42
A
723923
D
Common Stock
2020-11-02
4
S
0
11917
31.1329
D
712006
D
Common Stock
2020-11-02
4
S
0
83
31.875
D
711923
D
Common Stock
23090
I
See footnote
Common Stock
104449
I
See footnote
Common Stock
104449
I
See footnote
Common Stock
16579
I
See footnote
Common Stock
16579
I
See footnote
Stock Option (Right to Buy)
6.42
2020-11-02
4
M
0
3000
0.00
D
2029-08-13
Common Stock
3000
238616
D
Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Shares held by wife.
Shares held by David M. Epstein 2019 Trust For Elle. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Elle and may be deemed to beneficially own these securities.
Shares held by David M. Epstein 2019 Trust For Zoe. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Zoe and may be deemed to beneficially own these securities.
Shares held by David M. Epstein 2019 Trust For Robert. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Robert and may be deemed to beneficially own these securities.
Shares held by David M. Epstein 2019 Trust For Shelley. David M. Epstein is the trustee of the David M. Epstein 2019 Trust for Shelley and may be deemed to beneficially own these securities.
25% of the shares subject to this option vested and became exercisable on August 14, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
Officer Title: President and Chief Executive Officer
/s/ Brent Hatzis-Schoch, as Attorney-in-Fact
2020-11-03